問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Psychiatry

Division of Pediatrics

Taoyuan Chang Gung Memorial Hospital of The C.G.M.F.

Division of Psychiatry

更新時間：2023-09-19

黃玉書Huang, Yu-Shu
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -4 個月

  • az1109@cgmh.org.tw

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃玉書

List

13Cases

2026-08-01 - 2027-10-31

Phase III

Not yet recruiting
A phase 3, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of ALKS 2680 in adult patients with type 1 narcolepsy.

  • Condition/Disease

    narcolepsy

  • Test Drug

    ALKS 2680 2 mg tablet ALKS 2680 4 mg tablet ALKS 2680 6 mg tablet ALKS 2680 Placebo Tablet Orange

Participate Sites
5Sites

Not yet recruiting1Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

  • Condition/Disease

    Narcolepsy Type 2

  • Test Drug

    ALKS 2680

Participate Sites
3Sites

Recruiting3Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  • Condition/Disease

    Narcolepsy Type 1

  • Test Drug

    ALKS 2680

Participate Sites
3Sites

Recruiting3Sites

2009-06-01 - 2017-08-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-03-15 - 2025-05-15

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-10-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-01-02 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-03-15 - 2008-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-12-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-08-01 - 2015-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Study ended5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB